The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101 PRECISION-Panc is an ambitious programme of research that seeks to uncover the molecular profile of individual patients with pancreatic cancer, to learn more about the disease and to pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment PRECISION-Panc
We’re investing £10 million to speed up our understanding of pancreatic cancer and work towards personalising treatment.
PRECISION-Panc is an ambitious programme of research that seeks to uncover the molecular profile of individual patients with pancreatic cancer, to learn more about the disease and to pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment.
At £10 million, it’s our biggest standalone investment in pancreatic cancer research to date and builds on our strategic focus on the disease.
https://www.cancerresearchuk.org/funding-for-researchers/applying-for-funding/how-to-make-a-successful-application/successful-applicant-case-studies/case-studies-of-major-research-programmes/precision-panc